Product Quick Detail

Ziihera® (Zanidatamab) is a humanized IgG1-like bispecific antibody targeting HER2 for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). Delivered intravenously, Ziihera® (zanidatamab-hrii) is a sterile, preservative-free lyophilized powder for reconstitution, offered in a 300mg single-dose vial.

Minimum Order: 1

Packaging: N/A

Delivery: 15 Days

Type:Humanized IgG1-like bispecific monoclonal antibody targeting two non-overlapping extracellular domains (ECD2 and ECD4) of HER2.

Molecular Formula:C₅₅₅₃H₈₅₂₆N₁₄₈₂O₁₇₂₆S₃₆ (non-glycosylated)

Molecular Weight:Approximately 124.8 kDa

CAS Number:2169946-15-8

UNII:Z20OC92TDI

Form:Sterile, preservative-free lyophilized powder for reconstitution and intravenous infusion.

Concentration after reconstitution:50 mg/mL

Vial size:Single-dose vial containing 300 mg zanidatamab-hrii

Inactive ingredients:Polysorbate 20, sodium succinate, succinic acid, sucrose

Administration:Intravenous infusion at 20 mg/kg every 2 weeks (or weight-based flat dosing in some regimens)

Indications (approved):Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.

Manufacturer:Produced in Chinese hamster ovary (CHO) cells via recombinant DNA technology.

Developer/Licensee:Developed by Zymeworks; licensed to Jazz Pharmaceuticals (US, Europe, etc.) and BeOne Medicines (formerly BeiGene) for certain regions.